T2	condition 91 129	aromatase inhibitor-induced arthralgia
T3	eligibility 473 533	post-menopausal women who were beginning adjuvant AI therapy
T6	outcome-Measure 722 740	development of AIA
T7	total-participants 775 778	184
T8	total-participants 832 834	93
T11	outcome 1064 1077	developed AIA
T12	iv-bin-abs 1046 1048	25
T13	iv-bin-percent 1059 1062	54%
T14	cv-bin-abs 1091 1093	27
T15	cv-bin-percent 1104 1107	57%
T9	outcome 916 938	serum vitamin D levels
T1	intervention 31 40	high-dose
T4	control 48 72	standard-dose vitamin D3
T5	outcome 1284 1299	AIA development
